Bergan T, da Fonseca J
Department of Microbiology, University of Oslo, Norway.
Chemotherapy. 1991;37(6):413-9. doi: 10.1159/000238888.
The minimum inhibitory concentration (MIC) of the new penem ALP 201 was tested against 243 recent clinical isolates of which 95 were from the family Enterobacteriaceae, 50 were from the genus Streptococcus, 50 were Staphylococcus aureus and 48 were Staphylococcus epidermidis. An agar dilution technique was used to determine the MIC50 and MIC90 of ALP 201 in comparison with cefotaxime, cefuroxime, clindamycin, imipenem, piperacillin, tobramycin and vancomycin. Overnight cultures were suspended to produce inocula of 10(5) colonies from a replicator. ALP 201 was shown to have an activity similar to imipenem against most species; ALP 201 was less active than imipenem against Serratia spp. and was more active against S. epidermidis. beta-Lactamase production did not affect the activity of ALP 201. All the other compounds tested were less active than ALP 201 and imipenem.
对新型青霉烯类药物ALP 201进行了最低抑菌浓度(MIC)测试,受试对象为243株近期临床分离菌株,其中95株来自肠杆菌科,50株来自链球菌属,50株为金黄色葡萄球菌,48株为表皮葡萄球菌。采用琼脂稀释技术来确定ALP 201的MIC50和MIC90,并与头孢噻肟、头孢呋辛、克林霉素、亚胺培南、哌拉西林、妥布霉素和万古霉素进行比较。过夜培养物经悬液稀释,通过接种复制器制备含10(5)个菌落的接种物。结果显示,ALP 201对大多数菌种的活性与亚胺培南相似;ALP 201对沙雷菌属的活性低于亚胺培南,而对表皮葡萄球菌的活性更高。β-内酰胺酶的产生并不影响ALP 201的活性。所测试的所有其他化合物的活性均低于ALP 201和亚胺培南。